Tetranuclear Dy(III) Imine Complex for Enhanced Biological Activity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current Schiff base-metal complexes, particularly beyond mononuclear and binuclear forms, have limited biological and pharmaceutical activities, necessitating the development of new complexes with enhanced properties.

Innovation Solution

The coordination of Schiff base ligands to Dysprosium (Dy) ions in tetra nuclear distorted square anti-prism structures to form Dy4L4ES2(H2O)·H2O complexes, which exhibit enhanced biological activity comparable to standard drugs, with applications in cancer treatment, microbial infections, and antioxidant responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If mononuclear and binuclear Schiff base-metal complexes are used, then the structure is simpler and easier to synthesize, but the biological and pharmaceutical activities are limited

Engineering Contradiction:

Improvebiological and pharmaceutical activitiesVSAvoidcomplex structure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines multiple metal centers (mononuclear and binuclear units) into a single tetranuclear complex structure. This merging of structural units increases the complexity of the complex but simultaneously enhances the biological and pharmaceutical activities through cooperative effects among the multiple metal centers, thereby resolving the contradiction between structural simplicity and biological efficacy.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a composite tetranuclear complex structure that integrates multiple Schiff base ligands and metal ions in a specific arrangement. This composite structure leverages the synergistic interactions between different metal centers and ligands to achieve superior biological and pharmaceutical activities compared to simpler mononuclear or binuclear complexes.

Inventive Principle:

Principle #40Composite materials

2Reliability

If tetra nuclear distorted square anti-prism structures are formed, then the biological activity is enhanced, but the manufacturing complexity increases

Engineering Contradiction:

Improvebiological activityVSAvoidsynthesis complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The tetranuclear complex is constructed by segmenting the overall structure into repeating mononuclear and binuclear units that assemble in a distorted square anti-prism geometry. This segmentation approach allows for controlled self-assembly during synthesis, where simpler building blocks organize into the complex tetranuclear structure, thereby reducing the apparent manufacturing complexity while maintaining the enhanced biological activity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The synthesis methodology employs preliminary formation of stable mononuclear and binuclear Schiff base complexes as precursors. These pre-formed units then undergo controlled assembly to generate the final tetranuclear distorted square anti-prism structure. This preliminary action simplifies the overall manufacturing process by breaking down the complex synthesis into manageable sequential steps.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS11873313B1Development of novel tetra nuclear distorted square anti-prism Dy (III) imine complex for pharmaceutical and industrial applications

Publication Date: 2024.01.16 KING FAISAL UNIV

AI summary

Provided are tetra nuclear distorted square anti-prism Dy (III) imine complexes, and their use in pharmaceutical and industrial applications. These complexes can be formed as a Schiff base-metal complex. The Schiff base-metal complex can comprise a Dy4L4ES2(H2O) H2O complex, wherein L is 2-Ethoxy-6-[(2-hydroxy-phenylimino)-methyl]-phenol; and ES is deprotonated 3-ethoxysalicylaldehyde.